<DOC>
	<DOCNO>NCT00211419</DOCNO>
	<brief_summary>The purpose study evaluate safety combine juxtasclerally administer anecortave acetate 15 mg triamcinolone acetate 4 mg administer intravitreally follow photodynamic therapy verteporfin treatment exudative age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>Study Combination Anecortave Acetate Triamcinolone Acetonide Treatment Exudative Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<criteria>1 . A male female evidence exudative agerelated macular degeneration clinical/angiographic/optical coherence tomography ( OCT ) finding subfoveal choroidal neovascularization ( CNV ) respond current therapy 2 . Baseline bestcorrected visual acuity ( BCVA ) 20/40 20/640 3 . Patient must willing able comply protocol provide inform consent . 1 . Patients intravenous , subcutaneous , anticoagulant therapy ( exception aspirin antiplatelet therapy ) take 5 day holiday therapy prior injection procedure . Note : Patients oral anticoagulant therapy may consider participate physician responsible monitoring anticoagulant therapy agree patient may take 5 day holiday therapy prior anecortave injection . The attend doctor must notify principal investigator notification make part source documentation . Anticoagulant therapy may resume either even morning injection procedure . 2 . Patient known glaucoma steroid induce ocular hypertension 3 . Intraocular pressure 21 mmHg great time entry study 4 . Patient significantly compromise visual acuity study eye due concomitant ocular condition 5 . Patients undergone intraocular surgery within last 2 month capsulotomy within last month study eye 6 . Patient participate investigational drug study 7 . Inability obtain photographs document CNV ( include difficulty venous access ) 8 . Concomitant oral steroid topical ophthalmic steroid use 9 . SubTenon 's injection steroid within past 6 month 10 . Patient significant liver disease uremia 11 . Patient known adverse reaction indocyanine green , iodine , verteporfin , triamcinolone 12 . Patient pregnant nursing 13 . Age le 50 year old</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Exudative Age-Related Macular Degeneration</keyword>
	<keyword>AMD</keyword>
</DOC>